109182
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
纳米技术驱动的骨肉瘤治疗策略进展：免疫疗法与药物递送
Authors Su W, Li Y, Yang G, Zhao Y, Zhou X, Liu G, Huang X, Sohail MF, Hussain I , Liu Q , Chen F
Received 25 June 2025
Accepted for publication 7 October 2025
Published 24 October 2025 Volume 2025:20 Pages 12913—12937
DOI https://doi.org/10.2147/IJN.S549587
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Prof. Dr. RDK Misra
Wenwen Su,1 Yuanyuan Li,1 Guang Yang,2 Yangyang Zhao,1 Xinhao Zhou,1 Guangyao Liu,3 Xu Huang,4 Muhammad Farhan Sohail,5 Irshad Hussain,6 Qihui Liu,1 Fangfang Chen1
1Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, People’s Republic of China; 2Jilin Cancer Hospital, Changchun, Jilin Province, 130012, People’s Republic of China; 3Department of Orthopedics, China-Japan Union Hospital of Jilin University, Changchun, 130033, People’s Republic of China; 4Department of Radiology, The First Hospital of Jilin University, Changchun, 130021, People’s Republic of China; 5Riphah Institute of Pharmaceutical Sciences (RIPS), Riphah International University, Lahore Campus, Lahore, 54000, Pakistan; 6Department of Chemistry and Chemical Engineering, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore, Punjab, 54792, Pakistan
Correspondence: Qihui Liu, Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, People’s Republic of China, Tel +86-0431-84995312, Email liuqihui@jlu.edu.cn Fangfang Chen, Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, People’s Republic of China, Tel +86-0431-84995312, Email cff@jlu.edu.cn
Abstract: Osteosarcoma (OS), the most prevalent primary malignant bone tumor, exhibits highly aggressive and metastatic potential, accounting approximately 56% of all primary malignant bone malignancies. While neoadjuvant chemotherapy with surgery remains standard, challenges persist: suboptimal margins, non-specific drug biodistribution, and systemic toxicity. Nanomaterial engineering offers transformative multifunctional platforms, integrating biomimetic targeting, stimuli-responsive release, and theranostics to enhance tumor penetration and reduce off-target effects. Immunotherapy combats OS by activating antitumor immunity, reprogramming the immunosuppressive tumor microenvironment (TME), and synergizing with checkpoint inhibitors/cell therapies. Ligand-functionalized nanocarriers significantly improve chemotherapeutic bioavailability and targeting. This review systematically explores the dual role of nanoplatforms in osteosarcoma therapeutics: (1) immunotherapy via TME reprogramming and (2) precision oncology through advanced drug delivery paradigms, providing critical insights into their translational potential for overcoming current therapeutic bottlenecks and ultimately improving clinical outcomes for OS patients.
Keywords: nanomaterials, osteosarcoma, tumor microenvironment, immune regulation, drug delivery
1Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, People’s Republic of China; 2Jilin Cancer Hospital, Changchun, Jilin Province, 130012, People’s Republic of China; 3Department of Orthopedics, China-Japan Union Hospital of Jilin University, Changchun, 130033, People’s Republic of China; 4Department of Radiology, The First Hospital of Jilin University, Changchun, 130021, People’s Republic of China; 5Riphah Institute of Pharmaceutical Sciences (RIPS), Riphah International University, Lahore Campus, Lahore, 54000, Pakistan; 6Department of Chemistry and Chemical Engineering, Syed Babar Ali School of Science and Engineering, Lahore University of Management Sciences, Lahore, Punjab, 54792, Pakistan
Correspondence: Qihui Liu, Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, People’s Republic of China, Tel +86-0431-84995312, Email liuqihui@jlu.edu.cn Fangfang Chen, Key Laboratory of Pathobiology, Ministry of Education, Nanomedicine and Translational Research Center, China-Japan Union Hospital of Jilin University, Changchun, 130033, People’s Republic of China, Tel +86-0431-84995312, Email cff@jlu.edu.cn
Abstract: Osteosarcoma (OS), the most prevalent primary malignant bone tumor, exhibits highly aggressive and metastatic potential, accounting approximately 56% of all primary malignant bone malignancies. While neoadjuvant chemotherapy with surgery remains standard, challenges persist: suboptimal margins, non-specific drug biodistribution, and systemic toxicity. Nanomaterial engineering offers transformative multifunctional platforms, integrating biomimetic targeting, stimuli-responsive release, and theranostics to enhance tumor penetration and reduce off-target effects. Immunotherapy combats OS by activating antitumor immunity, reprogramming the immunosuppressive tumor microenvironment (TME), and synergizing with checkpoint inhibitors/cell therapies. Ligand-functionalized nanocarriers significantly improve chemotherapeutic bioavailability and targeting. This review systematically explores the dual role of nanoplatforms in osteosarcoma therapeutics: (1) immunotherapy via TME reprogramming and (2) precision oncology through advanced drug delivery paradigms, providing critical insights into their translational potential for overcoming current therapeutic bottlenecks and ultimately improving clinical outcomes for OS patients.
Keywords: nanomaterials, osteosarcoma, tumor microenvironment, immune regulation, drug delivery